GLP-1 receptor agonists are, without question, among the most clinically significant pharmacological advances in metabolic medicine in decades.
The data on cardiovascular risk reduction, glycemic control, and sustained weight loss are compelling. For the right patients, in the right clinical context, these medications can be genuinely life-changing.
But here’s the question I keep coming back to:
The benefits are real. The risks are under discussed.
GLP-1s are not over-the-counter supplements. They are chronic disease medications with real physiological consequences, intended to be prescribed within a clinical framework, monitored over time, and, according to their FDA labels, paired with meaningful behavioral and nutritional support.
Yet the care infrastructure around them has not kept pace with the prescribing volume.
Most people receiving these medications today do not have access to a registered dietitian. They are not getting structured lifestyle coaching. They are not being monitored for muscle loss, changes in bone density, nutrient deficiencies, or gastrointestinal complications, as increasingly documented in the clinical literature.
A Cleveland Clinic analysis of nearly 460,000 adults prescribed a GLP-1 drug found that almost one in five developed a nutrient deficiency within a year, many without realizing it.
That is not a minor side note. That is a clinical signal.
The potential to lose more than weight
SA Washington Post investigation found that tens of millions of people taking GLP-1 medications worldwide have turned what began as an obesity and diabetes treatment into what researchers are calling “modern medicine’s largest unplanned neuroscience experiment.”
Researchers studying teens and young women on GLP-1 medications found extensive changes in brain connectivity within only a few months, specifically in the salience network, which helps regulate attention.
GLP-1s have been shown to alter the brain systems involved in reward, craving, and motivation, but where does the line fall between quieting a person’s cravings and influencing neurological pathways we don’t yet fully understand?
Additionally, studies show that approximately 25% to 40% of weight loss during GLP-1 therapy may come from lean mass, which includes muscle, bone, and water, making certain groups such as older adults, women in perimenopause or postmenopause, or those with a low baseline muscle mass more vulnerable to the effects of muscle loss if they don’t have the proper care in place to offset these losses.
This does not mean that these medications are dangerous. In fact, there have been early indications that they may favorably impact such diseases as cancer, substance use disorder, and neurodegenerative conditions, in addition to the FDA-approved indications of diabetes, obesity, elevated cardiovascular risk, metabolic dysfunction-associated steatohepatitis (MASH), and obstructive sleep apnea. But the aforementioned uncertainties, beneficial or not, demand a clinical response.
Unfettered access creates new categories of risk
When clinical oversight is removed from the prescription pathway, as occurs in some delivery systems, several things can happen simultaneously:
- Patients who should not be on these medications receive them anyway
- Patients who need these medications don’t receive proper long-term support
- Muscle protection goes unaddressed
- Nutritional deficiencies may accumulate quietly
Muscle loss and malnutrition during GLP-1 use, as well as weight regain after GLP-1 discontinuation, are well documented. Most individuals who stop taking the medication without sustained lifestyle support regain a substantial portion of the weight they lost within a year. Additionally, any significant weight loss typically includes lean mass loss alongside fat, a clinically meaningful risk that requires protein guidance from a registered dietitian and resistance-training support.
Appropriate clinical oversight has the potential to meaningfully reduce these risks for patients who are prescribed GLP-1s. If access pathways don’t include wraparound cardiometabolic support, including what happens when the medication is discontinued, the clinical intervention is incomplete by design. Without it, patients may lose weight in ways that compromise long-term metabolic function rather than improve it.
What responsible access actually looks like
The answer to this is not to restrict access to patients who genuinely need these medications. Access barriers have caused real harm, and the clinical case for broader coverage is strong.
The answer is to insist that access comes with the right clinical infrastructure and wraparound support.
That means a clinical evaluation that goes beyond a body mass index (BMI) threshold, to include a symptom screen, behavioral health assessment, and a registered dietitian providing personalized Medical Nutrition Therapy, not as an optional add-on, but as a core component of metabolic care. It means physician oversight that continues beyond the initial prescription and a transition plan in the event that medication is discontinued, whether by choice, cost, side effects, or life circumstances.
It means approaching GLP-1s the way we do any other powerful chronic-disease medication: with the clinical rigor that pharmacology demands.
The question we should be asking
We have spent several years asking: How do we get more patients access to GLP-1s?
That is an important question, and it has driven meaningful progress.
But the question we now need to ask: What does it mean to give someone access to a powerful chronic disease medication without giving them the care that makes it safe and sustainable?
Access without comprehensive metabolic care is not the solution to the chronic disease burden that these medications have the potential to address.
The medication is not the problem. The absence of the clinical framework around it is.
It is up to the employer to build that framework deliberately into every access pathway, benefit design, and health plan coverage structure, or we will look back at this moment and wonder what we missed when the signals were already there.
